Order of the Supreme Court of India in the matter of Network of People Living With HIV/AIDS & Others Vs Union of India & Others dated 24/02/2025. The Supreme Court (SC), February 24, 2025 has directed all states to file their affidavits addressing concerns raised about antiretroviral therapy (ART) drugs …
Armed with a product patent regime and a string of large acquisitions, multinational drug companies are making a strong comeback in India. Ten multinational companies (MNCs)
Lack of transparency in clinical trial conduct, publication bias and selective reporting bias are still important problems in medical research. Through clinical trials registration, it should be possible to take steps towards resolving some of these problems. However, previous evaluations of registered records of clinical trials have shown that registered …
The Pediatric Dengue Vaccine Initiative (PDVI) is a product development partnership (PDP) based at the International Vaccine Institute (IVI) in Seoul, Korea, and is supported by the Bill & Melinda Gates Foundation. PDPs are nonprofit entities that seek to accelerate the development, evaluation, and introduction of vaccines, drugs, devices, diagnostics, …
Mumbai: Vaccines are back in favour. After being junked by pharma biggies some years back, now almost every drug major is investing in vaccines by acquiring or building on fresh capacities. The evidence lies in pharma biggie Pfizer acquiring Wyeth and domestic major Shantha Biotech being snapped up by Sanofi …
Gatifloxacin, an antibiotic widely prescribed for throat infection, and Tegaserod, a medicine for chronic constipation, are likely to be banned in India. The sub-committee of the government
We read with interest the recent article by Murki, et al. on impact of cephalosporins restriction on incidence of extended spectrum b-lactamases (ESBLs) producing gram negative bacteria. Antibiotics restriction and their cycling are no doubt proven strategies to limit emergence of resistant microbial flora, provided they are employed judiciously. However, …
New Delhi: The government will no longer allow popular drugs to be sold under the same name if their active ingredients have been changed. Pharmaceutical companies will now have to also change the brand name of the drug. This was decided by the Drug Controller General of India (DCGI), Dr …
After months of prevarication, the European Union has stated publicly that the free trade agreement (FTA) it signs with India will include provisions for data exclusivity because “it is extremely important for research and innovation’’. That’s what European Union ambassador Daniele Smadja told journalists in Delhi on January 21. Smadja’s …
A missing link in the biosimilar regulatory framework of US could delay and wipe off potential earnings worth billions of dollars from the kitty of India
THE India drug regulator has asked pharmaceutical firms to withdraw several medicines sold under the same brand name but used to treat different ailments as it leads to confusion and could harm consumers for taking a wrong medicine. On Monday, the Drug Controller General of India (DCGI), Surinder Singh, asked …
DRUG firm Glenmark Pharmaceuticals on Monday said it has achieved positive results in human trials for its new drug molecule Crofelemer, which is aimed at treating diarrhoea in adults. In a filing to the Bombay Stock Exchange (BSE), the firm said resolution of diarrhoea was significantly higher in human subjects, …
Govt Body Has Shortlisted 11 Chinese & 2 Italian Manufacturing Units For Inspection New Delhi: Chinese and Italian drug manufacturing units, from where drugs are imported into India in bulk, are now under the scanner. After several import licences of local agents of such overseas units were cancelled due to …
India Still Far From Becoming Hub For Medical Tests: Study New Delhi: India is far behind US and China when it comes to hosting global clinical trials, contrary to popular belief. According to data released by the US National Institutes of Health (USNIH), India is currently hosting 1,400 clinical trials …
